SLCTR_2018_029
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease (Diversity1)
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease
Gilead Sciences, Inc·Phase 3·Sri Lanka Clinical Trials RegistryRecruiting
Study focus
- Disease/Condition
- Crohn's Disease
- Study type
- Interventional
Sponsor & location
- Primary sponsor
- Gilead Sciences, Inc
- Location
- Australia, Austria, Belgium, Bulgaria, Canada, Croatia, Czech Republic, France, Georgia, Germany, Gr
Timeline & enrollment
- Phase
- Phase 3
- Start date
- Jul 31, 2019
- End date
- N/A
ICD-10 classifications
Crohn disease, unspecifiedOther Crohn diseaseCrohn disease of large intestineCrohn disease [regional enteritis]Crohn disease of small intestine
Data source
- Registry
- Sri Lanka Clinical Trials Registry
- Trial ID
- SLCTR_2018_029
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for SLCTR_2018_029 through Pure Global AI's free database. This Phase 3 trial is sponsored by Gilead Sciences, Inc and is currently Recruiting. The study focuses on Crohn's Disease.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Sri Lanka Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.